Newswire (Published: Monday, January 30, 2017, Received: Thursday, January 26, 2017, 7:42:39 PM CST)

Word Count: 417

New Prostate Cancer Findings from Johns Hopkins University Described (Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Researchers detail new data in Oncology - Prostate Cancer. According to news reporting out of Baltimore, Maryland, by NewsRx editors, research stated, "Despite the recent approval and widespread use of abiraterone acetate and enzalutamide for the treatment of castration resistant prostate cancer (CRPC), this disease still poses significant management challenges because of various tumor escape mechanisms, including those that allow androgen receptor (AR) signaling to remain active.These AR-related resistance mechanisms include AR gene amplification or over expression, constitutively active ligand-independent AR splice variants, and gain-of-function mutations involving the AR ligandbinding domain (LBD), among others. Therefore, the development of AR-targeted therapies that function independently of the LBD represents an unmet medical need and has the potential to overcome many of these resistance mechanisms."

Our news journalists obtained a quote from the research from Johns Hopkins University, "This article discusses N-terminal domain (NTD) inhibition as a novel concept in the field of AR-directed therapies for prostate cancer. AR NTD-targeting agents have the potential to overcome shortcomings of current hormonal therapies by inhibiting all forms of AR-mediated transcriptional activity, and as a result, may affect a broader AR population including mutational and splice variant ARs."

According to the news editors, the research concluded: "Indeed, the first clinical trial of an AR NTD inhibitor is now underway."

For more information on this research see: Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer. Oncologist, 2016;21(12):1427-1435. Oncologist can be contacted at: Alphamed Press, 318 Blackwell St, Ste 260, Durham, NC 27701-2884, USA (see also Oncology - Prostate Cancer).

Our news journalists report that additional information may be obtained by contacting E.S. Antonarakis, Johns Hopkins University, James Buchanan Brady Urol Inst, Dept. of Urol, Baltimore, MD, United States. Additional authors for this research include C. Chandhasin, E. Osbourne, J. Luo, M.D. Sadar and F. Perabo.

Keywords for this news article include: Baltimore, Maryland, United States, North and Central America, Transcription Factors, DNA-Binding Proteins, Drugs and Therapies, Prostatic Neoplasms, Androgen Receptors, Steroid Receptors, Prostate Cancer, Androgens, Oncology, Genetics, Johns Hopkins University.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


Johns Hopkins University


Central America
North America
United States
North Carolina
Baltimore County


Science and Technology
      Scientific Research
            Natural Sciences
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
      Treatments and Therapies